Tscan Therapeutics, Inc. Stock Price, News & Analysis

TScan Therapeutics (TCRX) reported Q1 2025 financial results and provided corporate updates. The company reported a net loss of $34.1 million on revenue of $2.2 million. R&D expenses increased to $29.8 million, while G&A expenses rose to $8.6 million. TScan maintains a strong financial position with $251.7 million in cash and equivalents, expected to fund operations into Q1 2027. Key upcoming milestones include updates from PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 trials by year-end, plans to initiate a TSC-101 registrational trial in H2 2025, and filing an IND for TSC-102-A0301. The company appointed Stephen Camiolo as SVP of Market Access and remains on track to dose its first multiplex TCR-T therapy patient in H1 2025.

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its upcoming presentation at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.

The event will take place from May 13-17 in New Orleans, LA, with both in-person and virtual attendance options. The company will present a poster focused on "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation."

• Presentation Date: Tuesday, May 13
• Time: 6:00 - 7:30 p.m. Central Time
• Location: Poster Hall, Hall I2
• Abstract Number: AMA1180

The presentation materials will be made available on TScan's website (tscan.com) in the "Publications" section after the presentation concludes.

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat scheduled for April 7, 2025, at 9:30 a.m. Eastern Time.

Interested parties can access the webcast through the 'Events and Presentations' section on TScan's website at ir.tscan.com. The replay will remain available for 90 days following the event.

TScan Therapeutics (TCRX) has appointed Stephen Camiolo as Senior Vice President of Market Access, bringing over 25 years of industry experience. Camiolo, who most recently served as Vice President of National Cell Therapy Account Teams at Iovance Biotherapeutics, has led 16 successful product launches, including three cell therapies.

The appointment comes as TScan prepares to launch a pivotal trial of TSC-101 for treating residual disease and preventing relapse in patients with AML, ALL, and MDS later this year. The company continues to advance enrollment in its PLEXI-T™ solid tumor program.

Prior to joining TScan, Camiolo held leadership positions at Iovance, where he led the strategic launch of AMTAGVI®, CRISPR Therapeutics, Gilead Sciences, and Kite Pharma, focusing on market access, pricing strategy, and commercial operations.

TScan Therapeutics (NASDAQ: TCRX) reported its Q4 and full-year 2024 financial results, highlighting progress in its cancer treatment pipeline. The company's ALLOHA™ Phase 1 heme trial showed promising results with only 2 of 26 patients relapsing compared to 4 of 12 in the control arm.

Key financial highlights include: Q4 2024 revenue of $0.7M (down from $7.2M in Q4 2023), full-year revenue of $2.8M (down from $21M in 2023), and a Q4 net loss of $35.8M. The company secured $30M through a registered direct offering at a 37% premium and refinanced its debt with a $52.5M term loan from SVB.

R&D expenses increased to $107.4M for 2024 (from $88.2M in 2023) due to expanded clinical trials. With $290.1M in cash and equivalents, TScan expects to fund operations into Q1 2027. The company plans to initiate a registration trial for TSC-101 in H2 2025 and anticipates presenting multiplex TCR-T therapy data in the second half of 2025.

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 1:10 p.m. Eastern Time at the Marriott Copley Place in Boston, MA.

Investors and interested parties can access the presentation through a webcast available on the 'Events and Presentations' section of TScan's website at ir.tscan.com. The webcast recording will remain accessible on the company's website for 90 days after the event.

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company specializing in TCR-engineered T cell therapies for cancer treatment, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company will engage in a fireside chat scheduled for Tuesday, February 25, 2025, at 10:00 a.m. Eastern Time.

Interested parties can access the webcast through the 'Events and Presentations' section on TScan's investor relations website at ir.tscan.com. The presentation recording will remain available for replay on the company's website for 90 days after the event.

TScan Therapeutics (NASDAQ: TCRX) has secured a $30 million registered direct offering through the sale of pre-funded warrants to Lynx1 Capital Management LP and its advised fund. The warrants, priced at $4.00 each, will allow the purchase of up to 7,500,000 shares of voting common stock at $0.0001 per share, representing a 37% premium to the last closing price and a 34% premium over the 10-day volume weighted average closing price.

The financing, expected to close around December 27, 2024, extends TScan's operational runway from Q4 2026 to Q1 2027. The transaction builds upon Lynx1's existing investment in TScan, demonstrating continued support for the company's development of TCR-T cell therapies for cancer treatment.

TScan Therapeutics (NASDAQ: TCRX) has secured a term loan facility of up to $52.5 million from Silicon Valley Bank (SVB). The first tranche of $32.5 million will retire existing convertible debt with K2 Health Ventures, with the remaining funds for general corporate purposes. A second $20.0 million tranche can be drawn through June 2026.

The loan bears interest at the greater of 7.00% or prime rate minus 0.75%, capped at 9.75%. Maturity is set for September 2029, with interest-only payments until September 2027, subject to meeting certain milestones. The company expects its cash resources to fund operations into Q4 2026.